ILEX Medical Ltd.

As of June 30, 2026, ILEX Medical Ltd. carries a market capitalization of 54.77B, placing it among publicly traded companies globally. Its enterprise value stands at 37.97B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, ILEX Medical Ltd. has 11.19M shares outstanding.

As of June 30, 2026, ILEX Medical Ltd. trades at a trailing price-to-earnings ratio of 14.07. The price-to-sales ratio is 0.62, and the price-to-book ratio stands at 0.82.

As of June 30, 2026, ILEX Medical Ltd. trades at an EV/EBITDA multiple of 3.85 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.43 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 7.64 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. ILEX Medical Ltd. trades at an EV/FCF ratio of 7.89, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 37.97B versus a market cap of 54.77B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, ILEX Medical Ltd. maintains a current ratio of 3.07, meaning it holds 3.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 7.32, indicating elevated leverage, while an interest coverage ratio of 35.13 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, ILEX Medical Ltd. posted a return on equity (ROE) of 5.85, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 5.02 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 4.09, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 5.74, useful for judging operating efficiency across full business cycles. The company generates approximately 246.96M in revenue per employee across its workforce of 358.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 4.06 indicates how many times ILEX Medical Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, ILEX Medical Ltd. recorded 1.46B in income tax expense. That works out to an effective tax rate of 27.25, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 5.35B, leaving 3.89B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, ILEX Medical Ltd.'s stock has declined approximately 32.89% over the past 52 weeks. The 50-day moving average sits at 4,956.82, while the 200-day moving average is 5,445.35.

Over the twelve months ended June 30, 2026, ILEX Medical Ltd. generated 88.53B in revenue and converted that into 3.89B in net income, yielding earnings per share of 347.81. EBITDA reached 9.85B, while operating income came in at 4.09B.

As of June 30, 2026, ILEX Medical Ltd. holds 21.70B in cash and equivalents against 4.90B in total debt, resulting in a net debt position of -18.37B. Total book value stands at 67.02B, with working capital of 42.53B providing operational flexibility.

ILEX Medical Ltd. produced 8.59B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -3.98B in capital expenditures, free cash flow totaled 4.61B - equivalent to 411.80 per share.

Over the twelve months ended June 30, 2026, ILEX Medical Ltd. posted a gross margin of 22.32, reflecting its pricing power and cost economics. The operating margin of 4.62 and net profit margin of 4.39 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, ILEX Medical Ltd. paid dividends of 198.68 per share. The dividend payout ratio of 57.12 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 8.41, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 6.72, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to ILEX Medical Ltd. shareholders.

ILEX Medical Ltd.'s most recent stock split took place on August 21, 2000 with a 1:9 split ratio.

As of June 30, 2026, ILEX Medical Ltd. has an Altman Z-Score of 3.67, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.